Filana Therapeutics, Inc. (FLNA) stock
FLNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$0.64+0.08 (+14.52%)
Close on Nov 20, 2026Market cap $30.98MP/E –Yield –
Filana Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Filana Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $15.66M, down 72.5% year over year. For fiscal 2025 it was $26.59M, down 61.8% from the year before. Over ten years it grew 18.4% a year on average. The highest annual figure on record is $89.42M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.59M | -61.8% |
| FY2024 | Dec 31, 2024 | $69.64M | -22.1% |
| FY2023 | Dec 31, 2023 | $89.42M | +31.4% |
| FY2022 | Dec 31, 2022 | $68.03M | +174.2% |
| FY2021 | Dec 31, 2021 | $24.81M | +735.7% |
| FY2018 | Dec 31, 2018 | $2.97M | -61.0% |
| FY2017 | Dec 31, 2017 | $7.62M | -17.0% |
| FY2016 | Dec 31, 2016 | $9.18M | +0.8% |
| FY2015 | Dec 31, 2015 | $9.10M | +24.6% |
| FY2014 | Dec 31, 2014 | $7.31M | +48.6% |
| FY2013 | Dec 31, 2013 | $4.92M | -35.3% |
| FY2012 | Dec 31, 2012 | $7.61M | -8.4% |
| FY2011 | Dec 31, 2011 | $8.30M | -47.3% |
| FY2010 | Dec 31, 2010 | $15.75M | -25.2% |
| FY2009 | Dec 31, 2009 | $21.06M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.30M | -35.4% |
| Q1 FY2026 | Mar 31, 2026 | $4.54M | -66.7% |
| Q4 FY2025 | Dec 31, 2025 | $3.85M | -81.2% |
| Q3 FY2025 | Sep 30, 2025 | $3.96M | -77.6% |
| Q2 FY2025 | Jun 30, 2025 | $5.12M | -66.3% |
| Q1 FY2025 | Mar 31, 2025 | $13.67M | -15.8% |
| Q4 FY2024 | Dec 31, 2024 | $20.53M | +9.6% |
| Q3 FY2024 | Sep 30, 2024 | $17.68M | -25.1% |
| Q2 FY2024 | Jun 30, 2024 | $15.20M | -39.1% |
| Q1 FY2024 | Mar 31, 2024 | $16.23M | -26.6% |
| Q4 FY2023 | Dec 31, 2023 | $18.73M | +6.1% |
| Q3 FY2023 | Sep 30, 2023 | $23.60M | +27.4% |
| Q2 FY2023 | Jun 30, 2023 | $24.97M | +8006.8% |
| Q1 FY2023 | Mar 31, 2023 | $22.12M | +3753.7% |
| Q4 FY2022 | Dec 31, 2022 | $17.65M | +882500.0% |
| Q3 FY2022 | Sep 30, 2022 | $18.53M | +1166.3% |
| Q2 FY2019 | Jun 30, 2019 | $308.00K | -78.9% |
| Q1 FY2019 | Mar 31, 2019 | $574.00K | -46.3% |
| Q4 FY2018 | Dec 31, 2018 | $2.00K | -99.9% |
| Q3 FY2018 | Sep 30, 2018 | $1.46M | -9.6% |
| Q2 FY2018 | Jun 30, 2018 | $1.46M | -52.2% |
| Q1 FY2018 | Mar 31, 2018 | $1.07M | -23.1% |
| Q4 FY2017 | Dec 31, 2017 | $1.54M | +15.7% |
| Q3 FY2017 | Sep 30, 2017 | $1.62M | -39.1% |
| Q2 FY2017 | Jun 30, 2017 | $3.06M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.39M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.34M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.66M | – |
See a number that looks wrong?